Hepatitis Inequalities Study

Not yet recruiting

• Conditions: Chronic Hepatitis B; HEPATITIS C VIRUS CHRONIC INFECTION

• Registration Number: NCT06596213
• Lead Sponsor: Chinese University of Hong Kong

Brief Summary

Health inequality in liver diseases including age, gender, ethnicity and socioeconomic status has been increasingly recognised and potentially hinder hepatitis elimination. Health inequality has significant impact to evaluate the impact diagnostic and treatment uptake rates of chronic viral hepatitis on risk of hepatocellular carcinoma (HCC), hepatic event and liver-related death in patients with chronic hepatitis B and/or C. To overcome the limitation of small prospective cohort study of limited recruitment period, retrieving information from the Clinical Data Analysis and Reporting System (CDARS) from Hospital Authority (HA) will be one of the best way to answer these questions.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-07
• Study First Submitted: 2024-09-11
• Study First Submitted QC: 2024-09-16
• Last Update Submitted: 2024-09-16
• Study First Posted: 2024-09-19
• Last Update Posted: 2024-09-19
• Study Start: 2024-10-01
• Primary Completion: 2030-12-31
• Study Completion: 2031-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100000

Inclusion Criteria

• Patients will be eligible if they have any of these viral markers (HBeAg / HBsAg / HBV DNA / HCV RNA) and/or any of the following diagnosis codes (ICD-9 070-070.9; 348.3, 349.82, 456, 456.2, 456.8, 567.2, 567.8, 570, 571.2, 571.5, 571.6, 572.2, 572.3, 572.4, 789.5) checked or coded in any public hospitals or clinics from 1 January 2000 to 31 March 2024.

Read More

Exclusion Criteria

• Patients with missing age, gender, ethnicity and socioeconomic status
• (Subgroup analysis for ethnicity and socioeconomic status) Patients with missing ethnicity and socioeconomic status
• Serious medical illnesses or malignancy with life expectancy <1 year

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety	From 1 January 2000 to 31 March 2024	Time from diagnosis of hepatitis to treatment.

Secondary Outcome Measures

Name	Time	Method
Safety	From 1 January 2000 to 31 March 2024	The composite endpoints of recurrence of hepatic events (e.g. HCC hepatic coma, portal hypertension, variceal bleeding, hepatorenal syndrome).